FR21C1039I2 - Composés destinés à traiter l'amyotrophie spinale - Google Patents
Composés destinés à traiter l'amyotrophie spinaleInfo
- Publication number
- FR21C1039I2 FR21C1039I2 FR21C1039C FR21C1039C FR21C1039I2 FR 21C1039 I2 FR21C1039 I2 FR 21C1039I2 FR 21C1039 C FR21C1039 C FR 21C1039C FR 21C1039 C FR21C1039 C FR 21C1039C FR 21C1039 I2 FR21C1039 I2 FR 21C1039I2
- Authority
- FR
- France
- Prior art keywords
- tuskive
- atrophy
- spinal
- compounds
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461993839P | 2014-05-15 | 2014-05-15 | |
| PCT/EP2015/060343 WO2015173181A1 (fr) | 2014-05-15 | 2015-05-11 | Composés pour le traitement d'une amyotrophie spinale |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR21C1039I1 FR21C1039I1 (fr) | 2021-10-15 |
| FR21C1039I2 true FR21C1039I2 (fr) | 2022-09-02 |
Family
ID=53175048
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR21C1039C Active FR21C1039I2 (fr) | 2014-05-15 | 2021-09-09 | Composés destinés à traiter l'amyotrophie spinale |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US9969754B2 (fr) |
| EP (3) | EP3143025B1 (fr) |
| JP (1) | JP6236173B2 (fr) |
| KR (2) | KR102256013B1 (fr) |
| CN (1) | CN106459092B (fr) |
| AR (1) | AR100442A1 (fr) |
| AU (1) | AU2015261046C1 (fr) |
| BR (1) | BR112016026205B1 (fr) |
| CA (1) | CA2948561C (fr) |
| CL (1) | CL2016002836A1 (fr) |
| CR (1) | CR20160518A (fr) |
| DK (1) | DK3143025T3 (fr) |
| EA (2) | EA035068B1 (fr) |
| ES (2) | ES2761423T3 (fr) |
| FR (1) | FR21C1039I2 (fr) |
| HR (2) | HRP20230637T1 (fr) |
| HU (2) | HUE046491T2 (fr) |
| IL (2) | IL248653B (fr) |
| LT (1) | LTPA2021010I1 (fr) |
| MA (2) | MA39995B1 (fr) |
| MX (1) | MX371050B (fr) |
| MY (1) | MY174284A (fr) |
| NL (1) | NL301128I2 (fr) |
| NO (1) | NO2021035I1 (fr) |
| NZ (1) | NZ725008A (fr) |
| PE (1) | PE20170128A1 (fr) |
| PH (1) | PH12016502081A1 (fr) |
| PL (2) | PL3663296T3 (fr) |
| PT (1) | PT3143025T (fr) |
| RS (1) | RS59718B1 (fr) |
| SG (1) | SG11201609497TA (fr) |
| SI (2) | SI3143025T1 (fr) |
| TW (1) | TWI667239B (fr) |
| UA (1) | UA119670C2 (fr) |
| WO (1) | WO2015173181A1 (fr) |
| ZA (1) | ZA201607026B (fr) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9586955B2 (en) | 2012-02-10 | 2017-03-07 | Ptc Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| JP6689197B2 (ja) | 2013-08-19 | 2020-04-28 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | スクリーニング方法 |
| US10882868B2 (en) * | 2014-05-15 | 2021-01-05 | Hoffmann-La Roche Inc. | Compounds for treating spinal muscular atrophy |
| CN107635999B (zh) | 2015-05-20 | 2020-09-25 | 豪夫迈·罗氏有限公司 | 用于治疗脊髓性肌萎缩的化合物 |
| WO2016196386A1 (fr) | 2015-05-30 | 2016-12-08 | Ptc Therapeutics, Inc. | Procédés de modulation de l'épissage de l'arn |
| EP3374362A1 (fr) * | 2015-11-12 | 2018-09-19 | H. Hoffnabb-La Roche Ag | Composés pour le traitement de la sclérose latérale amyotrophique |
| WO2017080967A1 (fr) * | 2015-11-12 | 2017-05-18 | F. Hoffmann-La Roche Ag | Compositions pour le traitement d'une amyotrophie spinale |
| KR102488323B1 (ko) | 2015-12-10 | 2023-01-12 | 피티씨 테라퓨틱스, 인크. | 헌팅턴병 치료 또는 개선을 위한 조성물 |
| CN108137579B (zh) | 2015-12-10 | 2022-01-07 | 豪夫迈·罗氏有限公司 | 桥连哌啶衍生物 |
| EA201991309A1 (ru) * | 2016-11-28 | 2019-11-29 | Способы модуляции сплайсинга рнк | |
| SG11201911615WA (en) | 2017-06-05 | 2020-01-30 | Ptc Therapeutics Inc | Compounds for treating huntington's disease |
| KR20200017476A (ko) | 2017-06-14 | 2020-02-18 | 피티씨 테라퓨틱스, 인크. | Rna 스플라이싱의 변경 방법 |
| CA3067591A1 (fr) | 2017-06-28 | 2019-01-03 | Ptc Therapeutics, Inc. | Procedes de traitement de la maladie de huntington |
| CA3067592A1 (fr) | 2017-06-28 | 2019-01-03 | Ptc Therapeutics, Inc. | Methodes de traitement de la maladie de huntington |
| SG11202002610TA (en) * | 2017-09-22 | 2020-04-29 | Hoffmann La Roche | Process for the prepration of 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one derivatives |
| AU2018344402B2 (en) | 2017-10-03 | 2024-08-29 | F. Hoffmann-La Roche Ag | New treatment of SMA |
| WO2019191092A1 (fr) | 2018-03-27 | 2019-10-03 | Ptc Therapeutics, Inc. | Composés pour le traitement de la maladie de huntington |
| EP3814360A1 (fr) | 2018-06-27 | 2021-05-05 | PTC Therapeutics, Inc. | Composés hétéroaryles pour le traitement de la maladie de huntington |
| MX2020014098A (es) | 2018-06-27 | 2021-05-27 | Ptc Therapeutics Inc | Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington. |
| JP7427252B2 (ja) | 2018-06-27 | 2024-02-05 | 株式会社リボルナバイオサイエンス | 脊髄性筋萎縮症の予防または治療剤 |
| TW202035411A (zh) | 2018-10-19 | 2020-10-01 | 瑞士商赫孚孟拉羅股份公司 | 吡啶并[1,2-a]嘧啶-4-酮衍生物之新型式、及調配物及製備方法 |
| WO2020249577A1 (fr) | 2019-06-12 | 2020-12-17 | F. Hoffmann-La Roche Ag | Nouveau traitement de sma |
| WO2021021775A1 (fr) | 2019-07-31 | 2021-02-04 | Teva Pharmaceuticals International Gmbh | Formes à l'état solide de risdiplam et leurs procédés de préparation |
| WO2022048675A1 (fr) * | 2020-09-07 | 2022-03-10 | 苏州科睿思制药有限公司 | Forme cristalline du risdiplam, son procédé de préparation et son utilisation |
| WO2022162107A1 (fr) | 2021-02-01 | 2022-08-04 | Sandoz Ag | Forme cristalline de risdiplam |
| EP4308577A1 (fr) * | 2021-03-17 | 2024-01-24 | F. Hoffmann-La Roche AG | Nouveaux dérivés de thiadiazolopyrimidone |
| MX2023010719A (es) | 2021-03-17 | 2023-09-20 | Hoffmann La Roche | Nuevos derivados de tiazolopirimidinona. |
| JP2024509995A (ja) | 2021-03-18 | 2024-03-05 | エフ． ホフマン－ラ ロシュ アーゲー | リスジプラムを調製するための方法 |
| WO2023057404A1 (fr) | 2021-10-06 | 2023-04-13 | F. Hoffmann-La Roche Ag | Nouvelle administration combinée |
| CN118005654A (zh) * | 2022-04-18 | 2024-05-10 | 深圳市塔吉瑞生物医药有限公司 | 取代的吡啶并嘧啶酮类化合物及包含该化合物的组合物及其用途 |
| WO2023240236A1 (fr) | 2022-06-10 | 2023-12-14 | Voyager Therapeutics, Inc. | Compositions et procédés pour le traitement de troubles liés à l'amyotrophie spinale |
| WO2024069646A1 (fr) * | 2022-09-26 | 2024-04-04 | Natco Pharma Limited | Procédé amélioré pour la préparation de risdiplam et de ses intermédiaires |
| TW202423419A (zh) | 2022-10-14 | 2024-06-16 | 美商建南德克公司 | 治療脊髓性肌肉萎縮症之方法 |
| WO2024154148A1 (fr) * | 2023-01-21 | 2024-07-25 | Harman Finochem Limited | Procédé de préparation de risdiplatine, nouveaux intermédiaires et leur procédé de préparation |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2191183T3 (es) * | 1996-08-06 | 2003-09-01 | Pfizer | Derivados 6,6- o 6,7-biciclicos que contienen pirido o pirimido sustituidos. |
| WO2009042907A1 (fr) | 2007-09-27 | 2009-04-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Composés d'isoindoline pour le traitement d'une amyotrophie spinale et autres utilisations |
| WO2009151546A2 (fr) * | 2008-05-27 | 2009-12-17 | Ptc Therapeutics, Inc. | Procédés de traitement d'une atrophie musculaire spinale |
| KR20100012134A (ko) | 2008-07-28 | 2010-02-08 | 신호열 | 마우스 |
| US8932818B2 (en) | 2008-08-13 | 2015-01-13 | Ptc Therapeutics, Inc. | Screening assays for compounds that modulate programmed ribosomal frameshifting |
| WO2010019326A1 (fr) * | 2008-08-14 | 2010-02-18 | Cardiac Pacemakers, Inc. | Évaluation et adaptation des performances d’une liaison de communication acoustique |
| USRE47689E1 (en) * | 2011-12-30 | 2019-11-05 | Ptc Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| US9586955B2 (en) * | 2012-02-10 | 2017-03-07 | Ptc Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| EP2872493B1 (fr) | 2012-07-13 | 2018-11-14 | Indiana University Research and Technology Corporation | 5,6,7-trimethoxy 4-phenyle quinoline-2-ones utilisables en vue du traitement de l'amyotrophie spinale |
| WO2017080967A1 (fr) | 2015-11-12 | 2017-05-18 | F. Hoffmann-La Roche Ag | Compositions pour le traitement d'une amyotrophie spinale |
-
2015
- 2015-05-11 NZ NZ72500815A patent/NZ725008A/en unknown
- 2015-05-11 MX MX2016014547A patent/MX371050B/es active IP Right Grant
- 2015-05-11 PL PL19200058.6T patent/PL3663296T3/pl unknown
- 2015-05-11 KR KR1020217002966A patent/KR102256013B1/ko active IP Right Grant
- 2015-05-11 CR CR20160518A patent/CR20160518A/es unknown
- 2015-05-11 EA EA201692280A patent/EA035068B1/ru active Protection Beyond IP Right Term
- 2015-05-11 ES ES15721701T patent/ES2761423T3/es active Active
- 2015-05-11 SI SI201531021T patent/SI3143025T1/sl unknown
- 2015-05-11 HU HUE15721701A patent/HUE046491T2/hu unknown
- 2015-05-11 EA EA202090486A patent/EA202090486A3/ru unknown
- 2015-05-11 EP EP15721701.9A patent/EP3143025B1/fr active Active
- 2015-05-11 HR HRP20230637TT patent/HRP20230637T1/hr unknown
- 2015-05-11 EP EP19200058.6A patent/EP3663296B1/fr active Active
- 2015-05-11 UA UAA201612716A patent/UA119670C2/uk unknown
- 2015-05-11 WO PCT/EP2015/060343 patent/WO2015173181A1/fr active Application Filing
- 2015-05-11 BR BR112016026205-0A patent/BR112016026205B1/pt active IP Right Grant
- 2015-05-11 MA MA39995A patent/MA39995B1/fr unknown
- 2015-05-11 DK DK15721701T patent/DK3143025T3/da active
- 2015-05-11 RS RS20191541A patent/RS59718B1/sr unknown
- 2015-05-11 SI SI201531952T patent/SI3663296T1/sl unknown
- 2015-05-11 PE PE2016002128A patent/PE20170128A1/es unknown
- 2015-05-11 CA CA2948561A patent/CA2948561C/fr active Active
- 2015-05-11 ES ES19200058T patent/ES2949660T3/es active Active
- 2015-05-11 MA MA051988A patent/MA51988A/fr unknown
- 2015-05-11 PL PL15721701T patent/PL3143025T3/pl unknown
- 2015-05-11 EP EP23169721.0A patent/EP4241772A3/fr active Pending
- 2015-05-11 SG SG11201609497TA patent/SG11201609497TA/en unknown
- 2015-05-11 MY MYPI2016001903A patent/MY174284A/en unknown
- 2015-05-11 JP JP2016567816A patent/JP6236173B2/ja active Active
- 2015-05-11 CN CN201580027306.9A patent/CN106459092B/zh active Active
- 2015-05-11 PT PT157217019T patent/PT3143025T/pt unknown
- 2015-05-11 KR KR1020167034983A patent/KR102213740B1/ko active IP Right Grant
- 2015-05-11 AU AU2015261046A patent/AU2015261046C1/en active Active
- 2015-05-14 AR ARP150101500A patent/AR100442A1/es not_active Application Discontinuation
- 2015-05-14 TW TW104115433A patent/TWI667239B/zh active
-
2016
- 2016-10-12 ZA ZA2016/07026A patent/ZA201607026B/en unknown
- 2016-10-19 PH PH12016502081A patent/PH12016502081A1/en unknown
- 2016-10-31 IL IL24865316A patent/IL248653B/en active IP Right Grant
- 2016-11-08 CL CL2016002836A patent/CL2016002836A1/es unknown
- 2016-11-14 US US15/351,267 patent/US9969754B2/en active Active
-
2019
- 2019-10-17 IL IL270027A patent/IL270027B/en active IP Right Grant
- 2019-11-29 HR HRP20192159TT patent/HRP20192159T1/hr unknown
-
2021
- 2021-09-09 FR FR21C1039C patent/FR21C1039I2/fr active Active
- 2021-09-10 NO NO2021035C patent/NO2021035I1/no unknown
- 2021-09-14 LT LTPA2021010C patent/LTPA2021010I1/lt unknown
- 2021-09-14 HU HUS2100037C patent/HUS2100037I1/hu unknown
- 2021-09-15 NL NL301128C patent/NL301128I2/nl unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR21C1039I2 (fr) | Composés destinés à traiter l'amyotrophie spinale | |
| ZA201608108B (en) | Huntington's disease therapeutic compounds | |
| DK3386511T3 (da) | Fremgangsmåder til behandling af huntingtons sygdom | |
| EP3448874A4 (fr) | Compositions pour le traitement de maladies | |
| EP3448875A4 (fr) | Compositions pour le traitement de maladies | |
| EP3448987A4 (fr) | Compositions pour le traitement de maladies | |
| DK3347030T3 (da) | Brug af pasteuriseret akkermansia til behandling af stofskiftesygdomme | |
| MA44702A (fr) | Compositions de suspension à libération prolongée | |
| DK3125875T3 (da) | Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande | |
| DK3474804T4 (da) | Medicinsk forbinding | |
| IL265528A (en) | aav therapy for Huntington's disease | |
| DK3240612T3 (da) | Fremgangsmåder til behandling af nethindesygdomme | |
| DK3362066T3 (da) | Kombinationsterapi til behandling af maligniteter | |
| EP3268086A4 (fr) | Lsd pour le traitement de la maladie d'alzheimer | |
| HK1244485A1 (zh) | 用於治療神經母細胞瘤的組合物 | |
| MA41169A (fr) | Composés antibactériens à large spectre d'activité | |
| IL259297A (en) | Heterocyclic compounds for the treatment of disease | |
| EP3316788A4 (fr) | Imagerie obstétricale sur le lieu de soin pour manipulateurs très peu ou non formés | |
| GB201612165D0 (en) | Combinations for the treatment of type 2 diabetes | |
| JP1671730S (ja) | 医療用加湿器用タブ用部品 | |
| DK3302573T3 (da) | Sammensætning til behandlingen af hjernelæsioner | |
| DK3506901T3 (da) | Anvendelse af kynurensyre til behandling af muskelatrofi | |
| DK3724173T3 (da) | Forbindelser til behandling af neuromuskulære lidelser | |
| DK3209295T3 (da) | Fremgangsmåder til behandling af øjenlidelser | |
| IT201600121617A1 (it) | Composizione per il trattamento del reflusso gastroesofageo |